Tests hint at trouble with pairing cystic fibrosis drugs

Combining two types of cystic fibrosis drugs may cancel out the benefits of one of the medications. In cultures of human cells, ivacaftor, the cystic fibrosis drug sold under the trade name Kalydeco, may destabilize proteins. These proteins are disease-related and are targeted and corrected by drugs such as lumacaftor, two teams report July 23 in Science Translational Medicine. The findings contrast with positive results recently released from one of the two large clinical trials that combine ivacaftor and lumacaftor.

Ashley Yeager is the associate news editor at Science News. She has worked at The Scientist, the Simons Foundation, Duke University and the W.M. Keck Observatory, and was the web producer for Science News from 2013 to 2015. She has a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT.

More Stories from Science News on Health & Medicine